Governance SANA AB

SANION

SE0005794617

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 21/07/2026 BST			5-day change	1st Jan Change
13.03 ^SEK	+0.70%		-0.08%	-38.54%

07-16	Syria seizes weapons hidden in tanker truck, says cargo was for Hezbollah	RE
07-06	France's Macron visits Syria, in first trip by an EU head of state since Assad toppled	RE

Executive Committee: SANA AB

Manager

Positions heldSince

Thomas Feldthus

66 year

Chief Executive Officer	29/04/2022
Founder	31/12/2010
Public Communications Contact	-

Palle Christophersen

68 year

Chief Tech/Sci/R&D Officer	31/12/2013
Founder	31/12/2010

Karin Nielsen

56 year

Chief Tech/Sci/R&D Officer

29/04/2022

Pierandrea Muglia

60 year

Chief Tech/Sci/R&D Officer

09/03/2025

Janus Schreiber Larsen

54 year

Chief Operating Officer	28/02/2025
Founder	31/12/2010

Johnny Stilou

59 year

Director of Finance/CFO

11/05/2025

Composition of the Board of Directors: SANA AB

Director

CommitteesSince

John Sørensen Haurum

63 year

Chairman	30/04/2025
Independent Dir/Board Member	28/05/2024

Anna Ljung

46 year

Compensation Committee	18/01/2018
Audit Committee Chair	18/01/2018

Carl Johan Bertil Sundberg

68 year

Audit Committee	31/12/2014
Compensation Committee Chair

Jørgen Drejer

71 year

Director/Board Member

30/04/2025

Latest Appointments: SANA AB

12-17	CNS Pharmaceuticals, Inc. Announces CEO Changes	CI
12-17	CNS Pharmaceuticals, Inc. Announces Management Changes	CI
12-17	Saniona AB Announces Executive Appointments	CI
28/05/25	Saniona AB Announces Board Changes	CI
12/05/25	Saniona Names New CFO	MT
12/05/25	Saniona Appoints Johnny Stilou As Chief Financial Officer	RE
12/03/25	Saniona AB Appoints Pierandrea Muglia as Chief Medical Officer	CI

More news

Former Officers and Directors: SANA AB

Insider

Positions held

SinceUntil

Anita Milland

Chief Administrative Officer	31/12/2015	29/04/2022
Director of Finance/CFO	29/04/2020	11/05/2025
Investor Relations Contact	23/03/2020	25/06/2020

Joseph deBethizy

Director/Board Member	29/04/2022	24/05/2022
Chairman	18/01/2018	29/04/2022
Independent Dir/Board Member	18/01/2018	24/05/2022

Robert Hoffman

Director/Board Member	15/09/2021	24/05/2022
Independent Dir/Board Member	15/09/2021	24/05/2022

Edward Saltzman

Director/Board Member

28/05/2019

24/05/2022

Rami Levin

Chief Executive Officer	06/01/2020	29/04/2022
President	06/01/2020	29/04/2022

Jason Amello

Director of Finance/CFO

14/09/2020

31/03/2022

Wendy Dwyer

Corporate Officer/Principal

14/09/2021

31/12/2021

Kyle Haraldsen

Corporate Officer/Principal

31/12/2020

Denelle Waynick

General Counsel

31/12/2020

Linea Aspesi

Human Resources Officer

30/09/2020

Trista Morrison

Public Communications Contact

14/09/2020

Rudolf Baumgartner

Chief Tech/Sci/R&D Officer

30/04/2020

Leif Jan Eugen Andersson

Director/Board Member	31/12/2013	-
Independent Dir/Board Member	31/12/2013	-

Anker Gunvald Lundemose

Director/Board Member	31/12/2013	-
Founder	31/12/2010	-

Claus Tycho Bræstrup

Director/Board Member	18/01/2018	-
Chairman	31/12/2013	18/01/2018
Founder	31/12/2010	-
Independent Dir/Board Member	-	-

Elna Lembrér Åström

Comptroller/Controller/Auditor

Belen Carrillo-Rivas

General Counsel

Age distribution of managers

Parity Men Women

Male	9
Female	1

Of which Executive Committee

Male	6
Female	0

Of which Directors

Male	3
Female	1

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-27 - Earnings release - Q2 2026

More about the company